Lenalidomide, adriamycin, and dexamethasone (RAD) dose levels explored in the phase 1 part
| Dose level . | Lenalidomide, mg (d) . | Adriamycin, mg/m2 (d) . | Dexamethasone, mg (d) . | Pegfilgrastim, mg (d) . |
|---|---|---|---|---|
| 1 | 10 (1-21) | 4 (1-4, cont.) | 40 (1-4 and 17-20) | |
| 2 | 10 (1-21) | 6 (1-4, cont.) | 40 (1-4 and 17-20) | |
| 3 | 10 (1-21) | 9 (1-4, cont.) | 40 (1-4 and 17-20) | |
| 4 | 15 (1-21) | 9 (1-4, cont.) | 40 (1-4 and 17-20) | |
| 4 + G | 15 (1-21) | 9 (1-4, cont.) | 40 (1-4 and 17-20) | 6 (6) |
| 5 + G | 25 (1-21) | 9 (1-4, cont.) | 40 (1-4 and 17-20) | 6 (6) |
| Dose level . | Lenalidomide, mg (d) . | Adriamycin, mg/m2 (d) . | Dexamethasone, mg (d) . | Pegfilgrastim, mg (d) . |
|---|---|---|---|---|
| 1 | 10 (1-21) | 4 (1-4, cont.) | 40 (1-4 and 17-20) | |
| 2 | 10 (1-21) | 6 (1-4, cont.) | 40 (1-4 and 17-20) | |
| 3 | 10 (1-21) | 9 (1-4, cont.) | 40 (1-4 and 17-20) | |
| 4 | 15 (1-21) | 9 (1-4, cont.) | 40 (1-4 and 17-20) | |
| 4 + G | 15 (1-21) | 9 (1-4, cont.) | 40 (1-4 and 17-20) | 6 (6) |
| 5 + G | 25 (1-21) | 9 (1-4, cont.) | 40 (1-4 and 17-20) | 6 (6) |
Cont. indicates continuous infusion.